UNCY — what changed in the latest 10-Q
A section-by-section comparison of UNCY's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-12 vs the prior 10-Q · 2026-05-12
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +10 | −6 | ~17 | 46 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 1 |
| Legal proceedings | Text added/removed | 0 | 0 | ~2 | 5 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | 0 | 0 | ~1 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-12
On June 30, 2026, we announced that we received a CRL from the FDA regarding the resubmitted NDA for OLC. The FDA has not raised any concerns regarding clinical efficacy or safety data, and no additional data was requested from Unicycive. The CRL is based on the same third-party manufacturing defici…
Research and development expenses increased by approximately $1.0 million, or 59%, from approximately $1.8 million for the three months ended June 30, 2025, to approximately $2.8 million for the three months ended June 30, 2026. This increase was primarily driven by a $0.9 million increase in non-ca…
General and administrative expenses increased by $2.1 million, or 41%, from approximately $5.2 million for the three months ended June 30, 2025, to approximately $7.4 million for the three months ended June 30, 2026. This increase was primarily driven by a $1.4 million increase in non-cash stock-bas…
Comparison of the Six Months Ended June 30, 2025, and 2026 (in thousands)
Research and development expenses increased by approximately $0.5 million, or 12%, from approximately $3.9 million for the six months ended June 30, 2025, to approximately $4.4 million for the six months ended June 30, 2026. This increase was primarily driven by a $0.9 million increase in non-cash s…
Text removed vs the prior filing · source: 10-Q · 2026-05-12
On April 6, 2026, Gaurav Aggarwal, M.D., one of our directors, resigned from our Board of Directors. Dr. Aggarwal’s resignation was not a result of any disagreement with us or our management or Board of Directors on any matter related to our operations, policies, or practices.
Research and development expenses decreased by approximately $0.6 million, or 26%, from approximately $2.2 million for the three months ended March 31, 2025 to approximately $1.6 million for the three months ended March 31, 2026. This decrease was primarily driven by a reduction in drug development …
General and administrative expenses increased by $1.0 million, or 17%, from approximately $5.8 million for the three months ended March 31, 2025 to approximately $6.8 million for the three months ended March 31, 2026. This increase was primarily driven by a $0.9 million increase in consulting and pr…
Since our formation through December 31, 2020, we have funded our operations with the sale of common and preferred stock, convertible notes and from a loan from our Chief Executive Officer and principal stockholder.
On November 13, 2024, we entered into a sales agreement, with Guggenheim Securities, LLC pursuant to which, we may offer and sell shares of common stock having an aggregate offering price of up to $50.0 million, subject to certain limitations and in accordance with the terms of the sales agreement, …
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice